These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 36354777)

  • 1. Immune Checkpoint Inhibitors Related to Cardiotoxicity.
    Chen R; Zhou M; Zhu F
    J Cardiovasc Dev Dis; 2022 Nov; 9(11):. PubMed ID: 36354777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.
    Zito C; Manganaro R; Ciappina G; Spagnolo CC; Racanelli V; Santarpia M; Silvestris N; Carerj S
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors.
    Chen R; Peng L; Qiu Z; Wang Y; Wei F; Zhou M; Zhu F
    Front Cardiovasc Med; 2021; 8():727445. PubMed ID: 34938778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in immune checkpoint inhibitors induced-cardiotoxicity.
    Li X; Peng W; Wu J; Yeung SJ; Yang R
    Front Immunol; 2023; 14():1130438. PubMed ID: 36911712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Complications in Immune Checkpoint Inhibition Therapy.
    Tajiri K; Ieda M
    Front Cardiovasc Med; 2019; 6():3. PubMed ID: 30729114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
    Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges.
    Gan L; Liu D; Ma Y; Chen X; Dai A; Zhao S; Jin X; Gu G
    Front Pharmacol; 2022; 13():962596. PubMed ID: 36110551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
    Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
    Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature.
    Agrawal N; Khunger A; Vachhani P; Colvin TA; Hattoum A; Spangenthal E; Curtis AB; Dy GK; Ernstoff MS; Puzanov I
    Case Rep Oncol; 2019; 12(1):260-276. PubMed ID: 31011325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach.
    Murtagh G; deFilippi C; Zhao Q; Barac A
    Front Cardiovasc Med; 2024; 11():1350585. PubMed ID: 38410245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety.
    Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
    Front Cell Dev Biol; 2022; 10():851032. PubMed ID: 35433707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Cardiotoxicity of Immune Checkpoint Inhibitors.
    Nardi Agmon I; Itzhaki Ben Zadok O; Kornowski R
    J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology.
    He Y; Yu H; Dai S; He M; Ma L; Xu Z; Luo F; Wang L
    Genes Dis; 2024 Mar; 11(2):807-818. PubMed ID: 37692505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity from immune checkpoint inhibitors.
    Michel L; Rassaf T; Totzeck M
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100420. PubMed ID: 31517036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
    Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
    Achim A; Liblik K; Gevaert S
    Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.